TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04296942

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brachyury-TRICOM
Description: Every three weeks, until cycle 9, then every 12 weeks: \*Recombinant MVA-Bavarian Nordic (BN)-Brachyury recommended phase 2 dose (R2PD): 4 injections of vaccines with 1 given subcutaneous (SC) in each extremity on Day 1 of Cycles 1 and 2. Each injection of MVA-BN-Brachyury consists of 2.0 x 10\^8 infectious units (Inf.U). \*Recombinant fowlpox virus (FPV)-BN-Brachyury: 1 injection given SC in one extremity on Day 1 of Cycles 3 and beyond. Each injection of FPV-BN-Brachyury consists of 1.0 x 10\^9 Inf.U.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brachyury-TRICOM
Description: Every three weeks, until cycle 9, then every 12 weeks: \*Recombinant MVA-Bavarian Nordic (BN)-Brachyury recommended phase 2 dose (R2PD): 4 injections of vaccines with 1 given subcutaneous (SC) in each extremity on Day 1 of Cycles 1 and 2. Each injection of MVA-BN-Brachyury consists of 2.0 x 10\^8 infectious units (Inf.U). \*Recombinant fowlpox virus (FPV)-BN-Brachyury: 1 injection given SC in one extremity on Day 1 of Cycles 3 and beyond. Each injection of FPV-BN-Brachyury consists of 1.0 x 10\^9 Inf.U.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brachyury-TRICOM
Description: Every three weeks, until cycle 9, then every 12 weeks: \*Recombinant MVA-Bavarian Nordic (BN)-Brachyury recommended phase 2 dose (R2PD): 4 injections of vaccines with 1 given subcutaneous (SC) in each extremity on Day 1 of Cycles 1 and 2. Each injection of MVA-BN-Brachyury consists of 2.0 x 10\^8 infectious units (Inf.U). \*Recombinant fowlpox virus (FPV)-BN-Brachyury: 1 injection given SC in one extremity on Day 1 of Cycles 3 and beyond. Each injection of FPV-BN-Brachyury consists of 1.0 x 10\^9 Inf.U.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: 5mg by mouth weekly (RP2D) administered by patient on Days 1, 8 and 15 of each cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M7824
Description: 1800mg via intravenous (IV) infusion every (q)3 weeks on Day 1 of each cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M7824
Description: 1800mg via intravenous (IV) infusion every (q)3 weeks on Day 1 of each cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M7824
Description: 1800mg via intravenous (IV) infusion every (q)3 weeks on Day 1 of each cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ado-trastuzumab emtansine
Description: 3.6mg/kg via intravenous (IV) infusion every (q)3 weeks on Day 1 of each cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ado-trastuzumab emtansine
Description: 3.6mg/kg via intravenous (IV) infusion every (q)3 weeks on Day 1 of each cycle.
Study: NCT06495411

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pranayama-
Description: Pain of patients will be evaluated with the Visual analog scale at the 6th hour, 12th hour, 24th hour and at discharge.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: deep breathing-
Description: Pain of patients will be evaluated with the Visual analog scale at the 6th hour, 12th hour, 24th hour and at discharge.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control
Description: Pain of patients will be evaluated with the Visual analog scale at the 6th hour, 12th hour, 24th hour and at discharge.
Study: NCT05224687

Intervention type: OTHER
Intervention: Retroactive review of patient data of those receiving a dose of daptomycin
Description: A retrospective analysis will be conducted using patient data of those receiving a dose of daptomycin at MCMC, Methodist Dallas Medical Center, Methodist Richardson Medical Center, or Methodist Mansfield Medical Center.

Intervention type: OTHER
Intervention: Retroactive review of patient data of those receiving a dose of daptomycin
Description: A retrospective analysis will be conducted using patient data of those receiving a dose of daptomycin at MCMC, Methodist Dallas Medical Center, Methodist Richardson Medical Center, or Methodist Mansfield Medical Center.
Study: NCT05122403

Intervention type: PROCEDURE
Intervention: MRgFUS central lateral thalamotomy
Description: MRgFUS central lateral thalamotomy is a minimally invasive and effective procedure for medication-refractory neuropathic pain patients.
Study: NCT06201065

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hepatic arterial infusion chemotherapy
Description: administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion chemotherapy
Description: administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib
Description: 12 mg (or 8 mg) once daily (QD) oral dosing
Study: NCT06184880

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: behavioral
Description: International Physical Activity (IPAQ) Questionnaire, Quality of Life Questionnaire QLQ-C30, HN 43 questionnaire, Multidimensional Fatigue Inventory (MFI) Questionnaire, Big Five Inventory Questionnaire, illness Identity Questionnaire,

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral
Description: International Physical Activity (IPAQ) Questionnaire, Quality of Life Questionnaire QLQ-C30, HN 43 questionnaire, Multidimensional Fatigue Inventory (MFI) Questionnaire, Big Five Inventory Questionnaire, illness Identity Questionnaire,

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sedentary
Description: Actimetry (cumulative time without movement over 24h, prolonged sedentary periods \>30 min without movement. Continuous recording 7 days prior to visit T0, T1, T2, T3, T4, T5

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sedentary
Description: Actimetry (cumulative time without movement over 24h, prolonged sedentary periods \>30 min without movement. Continuous recording 7 days prior to visit T0, T1, T2, T3, T4, T5
Study: NCT06201065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 12 mg (or 8 mg) once daily (QD) oral dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240 mg iv.drip Q3W
Study: NCT05752838

Intervention type: OTHER
Intervention: No intervention
Description: This is a survey study, and there were no intervention
Study: NCT06201065

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin , fluorouracil, and leucovorin
Description: FOLFOX-HAIC
Study: NCT06440317

Intervention type: DEVICE
Intervention: Hemofiltration membranes (the oXiris membrane® and the HF1400® membrane)
Description: The PRISMAFLEX® or PRISMAX® control unit (pre- and post-dilution with a prescribed treatment dose \> 25 ml/kg/h) with regional citrate anticoagulation and a substitution solution by PHOXILLUM will be used regardless of the type of membrane used (the oXiris membrane and the HF 1400 membrane), also as part of routine care provided in the ICU.
Study: NCT05265845

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention aims to support infant feeding decisions and teach responsive feeding strategies.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text4Baby
Description: Free health and wellness text messages timed to due date through pregnancy and up until the baby's first birthday.
Study: NCT04747808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LL-BMT1
Description: Drug-printed contact lens in both eyes
Study: NCT05583344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4532990
Description: GSK4532990 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4532990
Description: GSK4532990 will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.
Study: NCT06161480

Intervention type: DEVICE
Group type: OTHER
Intervention: Weighted Blanket
Description: Weighted Blanket is an occupational therapy modality which has been associated with significant increases in grounding, orientation to reality, soothing, and quality of life.
Study: NCT05327959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clavicle open reduction and internal fixation
Description: Clavicle open reduction and internal fixation using the A.L.P.S. Clavicle Plating System
Study: NCT06252987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: routine treatment
Description: Routine medical treatment, basic rehabilitation training and individualized cognitive training

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: routine treatment
Description: Routine medical treatment, basic rehabilitation training and individualized cognitive training
Study: NCT04349514

Intervention type: OTHER
Intervention: Natural history
Description: Longitudinal observation of neuroimaging, clinical, and blood markers.

Intervention type: OTHER
Intervention: Natural history
Description: Longitudinal observation of neuroimaging, clinical, and blood markers.
Study: NCT05057715

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VCN-01
Description: Intravenous administration of VCN-01

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VCN-01
Description: Intravenous administration of VCN-01

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VCN-01
Description: Intravenous administration of VCN-01

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: huCART-meso Cells
Description: Intravenous administration of huCART-meso cells

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: huCART-meso Cells
Description: Intravenous administration of huCART-meso cells

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: huCART-meso Cells
Description: Intravenous administration of huCART-meso cells
Study: NCT06313008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: eligible subjects were randomly and equally assigned to the empagliflozin add-on group (empagliflozin 10 mg/ day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 MG
Description: eligible subjects were randomly and equally assigned to vildagliptin add-on group (vildagliptin 50 mg/day as the initial dose).
Study: NCT05936385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyle
Description: Healthy lifestyle counseling and goal setting every month with a team of experts, mobile app with healthy lifestyle resources and goal tracking tool, access to social services and lifestyle programs in the community, and community health worker outreach every month.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Weight checks and lifestyle counseling with primary care provider every other month.
Study: NCT06462547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INZ-701
Description: INZ-701 is a recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody (rhENPP1-Fc).
Study: NCT05048082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegsitacianine
Description: An intraoperative nanoparticle-based fluorescence imaging agent comprised of micelles covalently conjugated to indocyanine green (ICG).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor resection surgery
Description: Standard of care surgical removal of cancerous lung lesion
Study: NCT06318026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Centralized Intervention
Description: A centralized intervention by a social worker or counselor, added to usual care that systematically offers outreach and shared decision-making for symptoms due to alcohol use

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary Care Intervention
Description: A primary care intervention added to usual care that uses state-of-the-art implementation interventions to systematically encourage primary care providers to offer routine shared decision-making for symptoms due to alcohol use.
Study: NCT06252987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: routine treatment
Description: Routine medical treatment, basic rehabilitation training and individualized cognitive training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: routine treatment
Description: Routine medical treatment, basic rehabilitation training and individualized cognitive training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-invasive brain stimulation
Description: tDCS\&rTMS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-invasive brain stimulation
Description: tDCS\&rTMS
Study: NCT06471140

Intervention type: OTHER
Intervention: magnetic resonance imaging (MRI)
Description: MRI performed three times during pregnancy and 6 months postpartum

Intervention type: OTHER
Intervention: magnetic resonance imaging (MRI)
Description: MRI performed three times during pregnancy and 6 months postpartum

Intervention type: OTHER
Intervention: magnetic resonance imaging (MRI)
Description: MRI performed three times during pregnancy and 6 months postpartum
Study: NCT06201065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin , fluorouracil, and leucovorin
Description: FOLFOX-HAIC
Study: NCT05078385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGLE-102
Description: AGLE-102, bone marrow mesenchymal stem cell derived extracellular vesicles (EVs)
Study: NCT06252987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-invasive brain stimulation
Description: tDCS\&rTMS
Study: NCT05538858

Intervention type: PROCEDURE
Intervention: Mechanical Ventilation
Description: Positive pressure mechanical ventilation
Study: NCT04753359

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Med
Description: Mediterranean diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Med
Description: Mediterranean diet
Study: NCT04842721

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic Saturated Saline Mouth Rinse Active Arm
Description: Each Patient of this groups will be asked to keep the solution still in his/her mouth, close to the back of the mouth, for 30 minutes without gargling and without swallowing. After 30 minutes the solution will be spit out and mouth will be rinsed with plain water several times. The process will be done twice a day for 2 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Plain Water Mouth Rinse Arm
Description: Each Patient of this groups will be asked to keep the water still in his/her mouth, close to the back of the mouth, for 30 minutes without gargling and without swallowing. After 30 minutes the water will be spit out. The process will be done twice a day for 2 days.
Study: NCT05301322

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF Vaccine
Description: RSV Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF Vaccine
Description: RSV Vaccine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal Inactivated Influenza Vaccine
Description: SIIV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal Inactivated Influenza Vaccine
Description: SIIV
Study: NCT04753359

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WL
Description: Measuring change in weight

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WL
Description: Measuring change in weight
Study: NCT05286112

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Description: 10 sessions focused on increasing mindfulness awareness to address thoughts, emotions, and behaviors that maintain functional impairment and risk of suicide.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Health education provides information on the importance and benefits of and guidelines for living a healthy lifestyle.
Study: NCT05629416

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interventions to transform the culture of healthcare systems to achieve excellence in providing culturally safe care for First Nations peoples
Description: 1. Implement 'Ask the Specialist Plus', a structured program to promote anti-racism within Northern Territory (NT) hospitals by giving healthcare providers training in cultural safety.~2. Implement strategies to foster 'Clinical champions of cultural safety' through a social media chat platform and face to face meetings to discuss anti-racism practice, cultural safety and practical ways to deliver culturally safe care including interpreter use.~3. Support simplified and improved strategies for booking an interpreter to increase uptake.~4. Implement retention strategies to ensure interpreters receive workplace support.~5. Provide training in health terminology for interpreters.~6. Integrate interpreter supply and demand through efficiency and effectiveness strategies tailored to participating sites.~7. Implement continuous quality improvement cycles with senior managers, using findings from qualitative and quantitative data collection and evaluation.
Study: NCT06274528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg
Description: Within FDA approved dose 10 mg; capsule; QD, 6 month duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 20mg
Description: 20 mg; capsule; QD; 6 month duration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg; capsule; QD; 6 month duration
Study: NCT04703218

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: olfactory rehabilitation
Description: Olfactory rehabilitation consists of smelling 4 scents twice a day using scent sticks, for 12 weeks
Study: NCT04824365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Pyruvate
Description: Subjects will use a sodium pyruvate nasal spray 3x daily for 14 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Subjects will use a saline nasal spray 3x daily for 14 days.
Study: NCT05123911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigational Shampoo
Description: Parent/LAR will bathe the child participant with the investigational shampoo at least 3 times a week for up to 28 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigational Conditioner
Description: Parent/LAR will bathe the child participant with the investigational conditioner at least 3 times a week for up to 28 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigational Combing Cream
Description: Parent/LAR will apply investigational combining cream to wet and previously moistened hair at least 3 times a week for up to 28 days.
Study: NCT04892810

Intervention type: PROCEDURE
Intervention: Percutaneous ablation
Description: Hepatic Percutaneous Ablation with radiofrequency or microwave
Study: NCT06113016

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study: NCT06453837

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mentha Suaveolens extract incorporated into a food supplement
Description: Each subject of this group takes 1 capsule of the food supplement per day, with lunch, for 84 consecutive days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo product
Description: Each subject of this group takes 1 capsule of comparator product per day, with lunch, for 84 consecutive days.
Study: NCT05318755

Intervention type: DRUG
Intervention: GAHT for transgender men
Description: Testosterone undecanoate

Intervention type: DRUG
Intervention: GAHT for transgender women
Description: Estradiol and antiandrogens (Spironolactone or Cyproterone acetate)
Study: NCT06036927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQC2731 injection
Description: TQC2731 injection is a thymic stromal lymphopoietin (TSLP) monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQC2731 injection
Description: TQC2731 injection is a thymic stromal lymphopoietin (TSLP) monoclonal antibody.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQC2731 matching placebo
Description: It'a a placebo injection without active substances.
Study: NCT05482425

Intervention type: OTHER
Group type: OTHER
Intervention: Autologous facial fat graft injection
Description: Participants will received either a washed or unwashed autologous facial fat graft injection to both sides of the face, as determined by randomization.

Intervention type: OTHER
Group type: OTHER
Intervention: Autologous facial fat graft injection
Description: Participants will received either a washed or unwashed autologous facial fat graft injection to both sides of the face, as determined by randomization.
Study: NCT05983627

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Umbilical Cord Mesenchymal Stem Cells
Description: The stem cell infusion route is peripheral intravenous infusion. All subjects received experimental drugs and conventional treatment during the study period.
Study: NCT05894031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wim Hof Method
Description: The intervention followed the guidelines provided by Wim Hof. The intervention comprised three components: cold water exposure, breathing exercise, and meditation.The participants were instructed to perform the WHM daily over the course of 15 days. The participants could choose when to do so throughout the day, however, the components were to be performed in a strict, sequential order: breathing exercises, followed by meditation, and then cold exposure. Participants were asked to complete a daily log in which they documented whether they performed the procedure and for how long. Altogether, the procedure lasted about 15 minutes.
Study: NCT02190786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KUX-1151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KUX-1151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KUX-1151
Study: NCT05467540

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPINERY
Description: Radio-Frequency device designed for palliative treatments of patient with painful metastatic bone tumors involving vertebral bodies, sacrum, iliac crest and peri-acetabulum